We’re excited to share a new study in the Journal of Clinical Medicine (JCM) MDPI highlighting the benefits of #NexoBrid® enzymatic debridement for treating small, deep partial-thickness burns on hands and feet. 📍 Conducted by Tokyo Medical and Dental University, this study showcases a minimally invasive approach that eliminates the need for conventional skin grafting. 🔗 Read the full study: https://lnkd.in/daSiFq7Y We’re proud to see NexoBrid® driving innovation in burn care globally. 🌍 #BurnCare #NexoBrid #Innovation #WoundCare #JournalOfClinicalMedicine
MediWound
Pharmaceutical Manufacturing
The global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair
עלינו
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com
- אתר אינטרנט
-
http://www.mediwound.com
קישור חיצוני עבור MediWound
- תעשייה
- Pharmaceutical Manufacturing
- גודל החברה
- 51-200 עובדים
- משרדים ראשיים
- Yavne
- סוג
- חברה ציבורית
- הקמה
- 2000
מיקומים
-
הראשי
קבלת הוראות הגעה
HaYarkon 42
Yavne, 8122745, IL
עובדים ב- MediWound
עדכונים
-
We’re excited to announce that MediWound will host a virtual KOL event on January 8, 2025. The event will feature leading clinical experts: 🔹 Dr. John Lantis II | Icahn School of Medicine at Mount Sinai 🔹 Dr. Vickie R Driver DPM MS FACFAS | Washington State University 🔹 Dr. Rob Snyder, DPM, MSc, MBA, CWSP, FFPM RCPS(Glasg) | Barry University School of Podiatric Medicine A live Q&A session with the KOLs and MediWound leadership will follow. Read more: https://lnkd.in/dW3j9-QH Register here: https://lnkd.in/dZkXk2V8 #WoundCare #EscharEx #ChronicWounds #VLUs #HealthcareInnovation
MediWound Virtual Key Opinion Leader (KOL) Event: EscharEx® Phase III VALUE Study in Venous Leg Ulcers and the Commercial Opportunity - LifeSci Events
https://lifescievents.com
-
🌟 New Review in the European Burn Journal! 🌟 We’re pleased to share a recently published review "Bromelain in Burn Care: Advancements in Enzymatic Debridement and Patient Outcomes". 📌 This latest review highlights the growing role of enzymatic debridement in modern burn treatment, offering critical insights into its clinical advantages and applications. The authors discuss the potential of enzymatic methods, such as NexoBrid®, to effectively treat even complex and large burn areas, transforming specialized burn care. 🔗 Read the full article here: https://lnkd.in/gHsaMTse #BurnCare #WoundHealing #EnzymaticDebridement #BurnTreatment #EuropeanBurnJournal
📢 A new Review by Dr. Eliza-Maria Bordeanu-Diaconescu and Dr. Sabina Grama's team: "Bromelain in Burn Care: Advancements in Enzymatic Debridement and Patient Outcomes" This latest review in the EBJ highlights the growing role of enzymatic debridement in modern burn treatment. 🔍 Key Takeaways: - Enzymatic debridement offers a less invasive approach compared to surgical excision. - It selectively removes necrotic tissue while preserving healthy tissue. - Benefits include faster debridement, fewer additional surgeries, and improved wound healing outcomes. The paper discusses the clinical advantages and important considerations for integrating enzymatic methods into specialized burn care. As evidence grows, enzymatic debridement is emerging as a promising tool for treating even complex and larger burn areas. 🔗 Read the full article here: https://lnkd.in/gHsaMTse #BurnCare #WoundHealing #EnzymaticDebridement #BurnTreatment #ModernMedicine #EuropeanBurnJournal #EBJ
-
-
We're #hiring a new PV Specialist - 180 in Yavne, Center District. Apply today or share this post with your network.
-
✨ Teamwork, Fun, and Inspiration in Tel Aviv! ✨ At MediWound, we know that great teamwork starts with strong relationships—and what better way to build those connections than through shared experiences? Our recent team trip to Tel Aviv was the perfect opportunity to step away from our daily routines, spend quality time together, and create unforgettable memories. From meaningful conversations to moments filled with laughter, this trip reminded us just how fortunate we are to work alongside such an incredible group of people. Here’s to the power of teamwork, shared adventures, and the inspiration we bring back to the office. We’re already looking forward to our next journey together! #TeamBuilding #CompanyCulture #EmployeeEngagement
-
-
We're #hiring a new Clinical QA Specialist - 209 in Yavne, Center District. Apply today or share this post with your network.
-
We're #hiring a new Document Control Coordinator - 206 in Yavne, Center District. Apply today or share this post with your network.
-
We're #hiring a new Pilot Process Specialist - 201 in Yavne, Center District. Apply today or share this post with your network.
-
We're #hiring a new Production Operator -103 in Yavne, Center District. Apply today or share this post with your network.